Jason Gerberry
Stock Analyst at B of A Securities
(3.80)
# 652
Out of 4,865 analysts
155
Total ratings
56.36%
Success rate
5.63%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LQDA Liquidia | Maintains: Buy | $25 → $23 | $13.59 | +69.24% | 2 | Jun 11, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $45 → $46 | $41.36 | +11.23% | 3 | Jun 5, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $20 → $22 | $16.89 | +30.25% | 14 | May 8, 2025 | |
| PCVX Vaxcyte | Maintains: Buy | $157 → $137 | $33.64 | +307.25% | 9 | Apr 1, 2025 | |
| IMVT Immunovant | Maintains: Buy | $38 → $33 | $15.31 | +115.55% | 5 | Mar 20, 2025 | |
| VTRS Viatris | Maintains: Underperform | $11 → $10 | $8.76 | +14.16% | 3 | Feb 28, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $143 → $167 | $101.60 | +64.37% | 5 | Feb 11, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Buy | $30 | $23.22 | +29.20% | 2 | Jan 9, 2025 | |
| ACLX Arcellx | Maintains: Buy | $84 → $100 | $62.88 | +59.03% | 4 | Nov 6, 2024 | |
| BHVN Biohaven | Maintains: Buy | $52 → $62 | $14.56 | +325.82% | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $3.06 | +684.31% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $0.86 | +249.69% | 3 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $68 | $36.15 | +88.11% | 5 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $19.73 | +1.37% | 3 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $27.92 | +11.03% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $600 → $550 | $10.28 | +5,250.19% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $29.77 | -2.57% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $37 | $15.50 | +138.71% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $31.70 | +76.66% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $32.44 | -7.52% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $63 | $25.65 | +145.61% | 1 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $204 → $217 | $107.05 | +102.71% | 5 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $4 → $2 | $5.88 | -65.99% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $791.24 | -36.81% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $1.30 | +592.31% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $9.85 | +153.81% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $3.40 | +47.06% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $5.73 | +371.20% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $0.76 | +2,538.52% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $10 | $0.64 | +1,458.85% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $185.48 | -48.78% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $47.23 | +27.04% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $37 | $24.00 | +54.17% | 4 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $78.28 | +14.97% | 11 | Oct 17, 2019 |
Liquidia
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $13.59
Upside: +69.24%
Exelixis
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $41.36
Upside: +11.23%
Teva Pharmaceutical Industries
May 8, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $16.89
Upside: +30.25%
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $33.64
Upside: +307.25%
Immunovant
Mar 20, 2025
Maintains: Buy
Price Target: $38 → $33
Current: $15.31
Upside: +115.55%
Viatris
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $8.76
Upside: +14.16%
Axsome Therapeutics
Feb 11, 2025
Maintains: Buy
Price Target: $143 → $167
Current: $101.60
Upside: +64.37%
Catalyst Pharmaceuticals
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $23.22
Upside: +29.20%
Arcellx
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $62.88
Upside: +59.03%
Biohaven
Sep 24, 2024
Maintains: Buy
Price Target: $52 → $62
Current: $14.56
Upside: +325.82%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $3.06
Upside: +684.31%
Sep 4, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $0.86
Upside: +249.69%
Jul 23, 2024
Maintains: Buy
Price Target: $67 → $68
Current: $36.15
Upside: +88.11%
Jun 11, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $19.73
Upside: +1.37%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $27.92
Upside: +11.03%
Mar 25, 2024
Maintains: Buy
Price Target: $600 → $550
Current: $10.28
Upside: +5,250.19%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $29.77
Upside: -2.57%
Jan 2, 2024
Maintains: Buy
Price Target: $29 → $37
Current: $15.50
Upside: +138.71%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $31.70
Upside: +76.66%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $32.44
Upside: -7.52%
Nov 17, 2023
Initiates: Neutral
Price Target: $63
Current: $25.65
Upside: +145.61%
Aug 10, 2023
Maintains: Buy
Price Target: $204 → $217
Current: $107.05
Upside: +102.71%
Aug 8, 2023
Downgrades: Underperform
Price Target: $4 → $2
Current: $5.88
Upside: -65.99%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $791.24
Upside: -36.81%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $1.30
Upside: +592.31%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $9.85
Upside: +153.81%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $3.40
Upside: +47.06%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $5.73
Upside: +371.20%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $0.76
Upside: +2,538.52%
Jul 15, 2020
Downgrades: Neutral
Price Target: $17 → $10
Current: $0.64
Upside: +1,458.85%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $185.48
Upside: -48.78%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $47.23
Upside: +27.04%
Oct 17, 2019
Reinstates: Neutral
Price Target: $37
Current: $24.00
Upside: +54.17%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $78.28
Upside: +14.97%